Scil Technology GmbH has established an independent service unit named formycon, which will provide protein characterization, formulation development, drug product manufacturing, process development, quality control, and analytics services.
Beaufort LLC, has added quality oversight to its services for clients in the pharmaceutical, diagnostic, and medical device industries.
Almac’s Clinical Services business unit was presented with the ASQ Philadelphia Section Large Company Member of the Year award at the section’s awards dinner.
Kathy Freeman has joined ACR Image Metrix as business development manager for the East Coast.
Leica Microsystems has released its SCN400 F combined fluorescent and brightfield digital slide scanner. The SCN400 F brings together Leica’s brightfield slide scanning capabilities and multi-channel fluorescence imaging in a single platform.
Thermo Fisher Scientific Inc. released the AssayAssure sample collection, transport, and storage products. AssayAssure is the one of the most flexible, widely applicable, and longest-acting universal preservatives currently available.
Hamilton Robotics introduces disposable CO-RE Piercing Tips for its MICROLAB STAR and NIMBUS automated liquid handling platforms. These tips are designed to pierce septa, sealing mats, and foils on tubes and plates.
Thermo Fisher Scientific Inc. announced that its Evolution 200 series of next-generation UV-Visible spectrophotometers has been named one of the most technologically significant products of the past 12 months by R&D Magazine.
Dynavax Technologies Corp. has reported a setback in a late-stage trial of its hepatitis B vaccine. The company said one production lot of Heplisav had a higher concentration of antibodies than the other two lots.
Gilead Sciences, Inc. announced Phase 3 clinical trial results showing that elvitegravir, an antiviral being evaluated for the treatment of HIV-1, was non-inferior to raltegravir after 48 weeks of therapy.
A long-delayed blood thinner from AstraZeneca PLC has won U.S. Food and Drug Administration approval, posing new competition to the multibillion-dollar blockbuster pill Plavix.
Eli Lilly and Co. said its second-quarter net income fell 11 percent, as increases in marketing and other expenses blunted the drugmaker's revenue growth.
Amag Pharmaceuticals Inc. said it will buy drugmaker Allos Therapeutics Inc. for stock valued at about $268 million in a deal designed to bolster their commercial portfolio and cuts costs.
Merck & Co. and Roche Holding AG, formerly bitter rivals in the hepatitis C drug market, have expanded their recent collaboration to jointly promote their drugs.
Bristol-Myers Squibb Company announced the results of a Phase II study evaluating the safety and tolerability of the investigational gamma secretase inhibitor BMS-708163 in patients with mild-to-moderate Alzheimer’s disease.